Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Degludec Review Could Lead To New CV Safety Requirements For Insulins

Executive Summary

During an advisory committee review of Novo Nordisk’s long-acting basal insulin, FDA raises concerns about a cardiovascular risk signal seen across a meta-analysis of clinical trials, although insulins have been excluded from CV safety requirements for type 2 diabetes drugs.

You may also be interested in...



FDA: No Decision On CV Outcomes Trial For Afrezza

Despite the apparent lack of a cardiovascular safety signal in the inhaled insulin’s clinical program, agency says the question of whether a dedicated study would be required post-approval “is still under discussion.”

Afrezza Review Shows Need For Patient-Driven Endpoints In Diabetes

Hemoglobin A1c levels are not particularly meaningful to patients more interested in heading off a hypoglycemia event, FDA advisory committee’s patient representative says. Panel votes to approve MannKind’s inhaled insulin despite agency’s efficacy questions and view that a hypoglycemia benefit was not shown.

Novo’s Insulin Degludec Faces Advisory Cmte. Scrutiny On Hypoglycemic Benefit, CV Safety

In briefing documents for the Nov. 8 panel review, FDA suggests the clinical trial data do not support Novo Nordisk’s assertion of a hypoglycemia advantage with its new long-acting insulin. Agency also raises concerns about a meta-analysis suggesting an increased cardiovascular risk.

Topics

Related Companies

UsernamePublicRestriction

Register

PS054880

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel